Ascendis Pharma (NasdaqGS:ASND) Valuation: Is There More Upside After Recent Share Price Gains?

Ascendis Pharma (ASND) has been gaining attention as investors take stock of its recent 8% rise over the past 3 months. The company’s share price is moving up as it shows consistent improvement in annual revenue and net income growth.

See our latest analysis for Ascendis Pharma.

Ascendis Pharma’s impressive run so far this year, with a share price up over 52% year-to-date, is attracting fresh interest from the market. That momentum is supported by a standout 62% total shareholder return over the past year, signaling investors are warming to its long-term growth story even as new catalysts emerge in the sector.

If strong pharma momentum has you curious, it may be the perfect moment to browse other discoveries with our healthcare stocks screener. See the full list for free.

But with shares trading at just over $210 and still about 22% below the average analyst price target, investors are left wondering if Ascendis Pharma remains undervalued or if future growth is already reflected in its current price.

Most Popular Narrative: 18.7% Undervalued

Compared to Ascendis Pharma's last close at $210.49, the most widely followed narrative assigns a fair value near $258.77, suggesting upside beyond recent gains. This valuation reflects both optimism and debate around future growth drivers and their sustainability.

Robust adoption and accelerating global launch of YORVIPATH, underpinned by strong demand, broad payer approvals, expanding commercial reach to more countries, and label expansion efforts (such as wider indications and higher dosing), is expected to drive sustained top-line revenue growth and support margin leverage as the installed patient base increases and access improves.

Read the complete narrative.

Want to know why analysts see more room for the stock to climb? Deep inside this narrative are bold forecasts for recurring sales growth, market expansion, and sharper profit margins. Which of these wildcards tips the fair value so high? See what quantitative targets drive the estimate. Click through and discover what most investors are missing.

Result: Fair Value of $258.77 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, factors such as slower-than-expected Yorvipath uptake or increased pricing pressure in key markets could quickly challenge bullish projections for Ascendis Pharma.

Find out about the key risks to this Ascendis Pharma narrative.

Build Your Own Ascendis Pharma Narrative

Curious to see things differently or eager to dig into the numbers yourself? In just a few minutes, you can piece together your own view of what’s ahead. Do it your way

A great starting point for your Ascendis Pharma research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.

Looking for More Investment Ideas?

Ready for your next smart move? Find unique, data-driven stock picks that could spark your portfolio’s growth. Don’t wait until these trends become yesterday’s news.

• Tap into the potential of high-yield investments and strengthen your income strategy through these 17 dividend stocks with yields > 3%, offering reliable returns above 3%.
• Ride the wave of disruptive technology by checking out these 25 AI penny stocks, where AI-driven businesses are transforming the market landscape.
• Catch the next undervalued opportunity and aim for outsized gains by reviewing these 918 undervalued stocks based on cash flows based on robust cash flow analysis.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com